Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.

7.29 0.11 −1.49%
Market cap
$456.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
577.09 1,121.34 720.95 977.18
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(33.41) (80.03) (57.88) (50.81)
P/B ratio
3.06 6.24 4.41 5.64
EV/Sales
382.70 920.42 545.04 787.71
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(6.82) (16.04) (9.65) (9.66)
Current Ratio
8.35 5.18 5.96 4.47
Net Debt/EBITDA
9.68 10.21 9.94 7.11
Debt/Equity
0.01 0.01 0.01 0.02
Earnings Yield
(12.55%) (8.01%) (11.37%) (14.33%)
Free Cash Flow Yield
(9.73%) (5.12%) (7.83%) (8.35%)
Free Cash Flow per Share
(0.42) (0.33) (0.34) (0.35)
Book value per Share
4.53 4.26 4.53 3.12
Free Cash Flow
(25.45) (19.58) (18.01) (18.32)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates